Skip to content

Elevated lipoprotein(a) and prevalent cardiovascular disease burden in treated hypertension.

Aug 2026 · Journal of Clinical Lipidology · 0 citations · 27 references
Medicine

TL;DR

In adults with treated HTN, elevated Lp(a) was independently associated with prevalent cardiovascular disease burden after adjustment for office BP control and conventional cardiovascular risk factors, and the potential role of Lp(a) assessment in refining cardiovascular risk stratification in treated hypertensive populations is supported.

Abstract

Background

Elevated lipoprotein(a) [Lp(a)] is associated with atherosclerotic cardiovascular disease across multiple clinical settings, but its relationship with prevalent cardiovascular disease burden among adults with treated hypertension (HTN) remains incompletely characterized.

Objective

To evaluate the association between elevated Lp(a) levels and prevalent cardiovascular disease burden among adults with treated HTN after adjustment for contemporaneous office blood pressure (BP) control.

Methods

We performed a predefined cross-sectional subanalysis of the multicenter Argentine Group for the Study of Lp(a) cohort, including adults with treated HTN and available Lp(a) measurements. BP control was defined as office BP ≤130/80 mmHg. Lp(a) was analyzed as a continuous variable using a high-risk threshold of ≥125 nmol/L. Multivariable generalized estimating equation models adjusted for age, sex, diabetes mellitus, smoking status, low-density lipoprotein-cholesterol, statin therapy, and BP control were used to evaluate the association between Lp(a) and prevalent cardiovascular disease burden.

Results

Among 2313 patients with treated HTN, higher Lp(a) levels were independently associated with a greater prevalence of cardiovascular disease burden. Each 1-SD increase in log-transformed Lp(a) was associated with higher odds of prevalent cardiovascular disease burden (Odds ratio [OR] 1.24; 95% CI 1.09-1.41; P = .001). Participants with Lp(a) ≥125 nmol/L had significantly higher odds of prevalent cardiovascular disease burden (OR 1.38; 95% CI 1.02-1.88; P = .037). Additional adjustment for body mass index and ethnicity yielded consistent results. No significant interaction was observed between Lp(a) levels and BP control status.

Conclusion

In adults with treated HTN, elevated Lp(a) was independently associated with prevalent cardiovascular disease burden after adjustment for office BP control and conventional cardiovascular risk factors. These findings support the potential role of Lp(a) assessment in refining cardiovascular risk stratification in treated hypertensive populations.

View source

Similar papers

Open access Sep 2026

Prevalence of Elevated Lipoprotein(a) and Its Association with Cardiovascular Disease in Patients with Overweight and Obesity in Argentina

Elevated Lp(a) was independently associated with IHD across all BMI categories, without significant interaction between BMI and Lp(a), and these findings support consideration of Lp(a) assessment across the BMI spectrum.

Ezequiel Forte, M. Arrupe, Leonardo Bufi et al. · 0 citations
Review Aug 2026

Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.

Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).

José Pablo Miramontes González · 0 citations
Open access Aug 2026

The impact of lipoprotein(a) determination in cardiovascular risk stratification among people living with HIV

In this cohort of virologically suppressed PLHIV, a non-significant inverse trend was observed between ART duration and Lp(a) levels and in the subgroup of moderate-to-high cardiovascular risk, the prevalence of coronary plaque vulnerability features was higher among those with elevated Lp(a), although the small number...

Carmen Ramos Alejos-Pita, D. Rodríguez Torres, Tatiana Mata Forte et al. · 0 citations
Open access Sep 2026

Blood pressure and cardiovascular risk in adults with non-proteinuric chronic kidney disease without diabetes.

A U-shaped association observed among individuals receiving antihypertensive treatment suggests that the relationship between BP and cardiovascular risk may be complex in this population, highlighting the potential importance of individualized clinical assessment.

Yuta Suzuki, Masachika Nishikawa, Hidehiro Kaneko et al. · 0 citations
#gene editing Open access Sep 2026

Lipoprotein(a) as an independent cardiovascular risk factor

Emerging evidence links Lp(a) to atrial fi brillation, broadening its clinical relevance and integrating Lp(a) testing into risk assessment and preparing for targeted therapies are critical steps in modern cardiovas-cular prevention.

L. Kopaleishvili, T. Chkhaidze, S. Ungiadze et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.